Axsome Therapeutics, Inc.
AXSM
Rang in Aktien
#2362
Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to... Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for a range of central nervous system (CNS) disorders within the United States. Its robust product pipeline features several promising candidates, including: AXS-05, an investigational therapy currently being developed for major depressive disorder and treatment-resistant depression. This compound is also in Phase III clinical evaluation for Alzheimer's disease agitation and has successfully finished Phase II trials investigating its use for smoking cessation. AXS-07, a novel, orally administered, rapidly-acting investigational medicine that employs multiple mechanisms of action. It has concluded two Phase III studies for the acute treatment of migraine attacks. AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is presently undergoing a Phase III trial for narcolepsy. AXS-14, an oral investigational drug, advancing through Phase III trials for the management of fibromyalgia. Axsome Therapeutics also engages in a research collaboration with Duke University to further assess AXS-05's potential in smoking cessation. The company, established in 2012, has its main offices in New York, New York.
Aktienkurs
$159.65
Zuletzt synchronisiert: 2026-10-20
Marktkapitalisierung
$8.36B
Veränderung (1 Tag)
2.46%
Veränderung (1 Jahr)
21.51%
Land
US
Handel Axsome Therapeutics, Inc. (AXSM)
Kategorie
Healthcare
Anzahl der ausstehenden Aktien von Axsome Therapeutics, Inc. (AXSM)
Anzahl der ausstehenden Aktien zum June 2026: 51.50M
Laut den neuesten Finanzberichten und dem Aktienkurs von Axsome Therapeutics, Inc. beträgt die aktuelle Anzahl der ausstehenden Aktien 51.50M. Am Ende von December 2023 hatte das Unternehmen 45.43M ausstehende Aktien. Die Anzahl der ausstehenden Aktien wird normalerweise durch Aktiensplits und Aktienrückkäufe beeinflusst.
Verlauf der ausstehenden Aktien von Axsome Therapeutics, Inc. (AXSM) von 2013 bis 2026
Ausstehende Aktien am Ende jedes Jahres
| Jahr | Ausstehende Aktien | ändert |
|---|---|---|
| 2026 (TTM) | 51.50M | 7.49% |
| 2024 | 47.91M | 5.48% |
| 2023 | 45.43M | 11.73% |
| 2022 | 40.66M | 8.07% |
| 2021 | 37.62M | 1.11% |
| 2020 | 37.21M | 9.37% |
| 2019 | 34.02M | 26.55% |
| 2018 | 26.88M | 18.09% |
| 2017 | 22.76M | 18.87% |
| 2016 | 19.15M | 60.32% |
| 2015 | 11.95M | -6.08% |
| 2014 | 12.72M | 62.59% |
| 2013 | 7.82M | 0.00% |
Ausstehende Aktien bei ähnlichen Unternehmen oder Wettbewerbern
| Unternehmen | Ausstehende Aktien | Unterschied | Land |
|---|---|---|---|
| 253.90M | 393.00% |
US
|
|
| 396.00M | 668.92% |
US
|
|
| 478.91M | 829.91% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | 20.75% |
NL
|
